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Abstract
Background: Invasive aspergillosis (IA) is an important cause of morbidity and mortality in immunocompromised
individuals. This study was conducted to identify a desirable target DNA sequence for the diagnosis of aspergillosis
using real-time quantitative polymerase chain reaction (qPCR).
Methods: Genomic DNA was extracted from Aspergillus, Candida, and bacteria species, and qPCR was applied to
validate a partial ribosomal DNA 28S-ITS2 sequence. Ethylenediaminetetraacetic acid-anticoagulated blood samples were
collected from 72 febrile hematological patients, while total DNA was isolated from plasma and whole blood for the
Aspergillus qPCR. The results were analyzed using a receiver operating characteristic curve. All cases were evaluated using
the revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group
and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) diagnostic criteria.
Results: Use of qPCR yielded positive results for 15 Aspergillus species but negative results for Candida species, bacterial
strains, and human DNA. The limit of detection was one copy per microliter of DNA. Analytical sensitivity and specificity
were six copies of DNA and 100%, respectively. The standard curve showed that qPCR was reliable for Aspergillus
detection and that significantly more DNA copies were obtained from whole blood than from plasma (P < 0.001). At a
cut-off value ≥ 25 copies/μL, the diagnostic sensitivity and specificity for IA using 28S-ITS2 qPCR were 90.9% and 73.4%,
respectively.
Conclusions: The use of qPCR with whole blood to detect and verify the 28S-ITS2 sequence is a specific and useful way
to diagnose IA.
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Background
Invasive aspergillosis (IA) is an important cause of
morbidity and mortality in immunocompromised
individuals. Patients at the highest risk are those with
prolonged periods of neutropenia due to chemotherapy for
acute leukemia or hematopoietic stem cell transplantation
(HSCT) for hematological malignancies or solid tumors
[1,2]. Conventional diagnostic tests such as blood cultures
are not useful or practical for the diagnosis of Aspergillus
spp. fungemia [3]. Further, non-culture–based techniques
used in the past lack the sensitivity and specificity needed
for the testing of immunocompromised patients [4-7].
Additionally, established IA is difficult to treat and has a
death rate of 80–90%, which has driven researchers to
develop more reliable and effective methods for its timely
diagnosis [1,2,8,9]. Polymerase chain reaction (PCR) assays
(conventional, nested, and real-time) have recently been
developed for diagnosing fungal infections, especially
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quantitative real-time PCR (qPCR), which shows better
potential for clinical application [1,10-14]. A range of gene
region targets (cytochrome p450; heat shock proteins; the
18S, 5.8S, and 28S domains; and the internal transcribed
space [ITS]) have been used in studies employing qPCR
methods. Over the past few years, the ribosomal DNA
gene region, composed of the 18S (1800 bp), 5.8S
(159 bp), and 28S (3396 bp) genes, has been shown to be
a promising target in which the three above-mentioned
genes are separated by the ITS1 (361 bp) and ITS2
(231 bp) genes. Until now, numerous studies have used
target sequences from this region to detect Aspergillus
DNA using PCR methods [10,15-18]. However, a consen-
sus is not available with regard to the specific target
sequence, specimen type, extraction method, or PCR
format and platform. Hence, the objectives of our study
were to search for a new potential target sequence for
Aspergillus, assess the qPCR value, and determine the qPCR
cut-off index for the presumptive clinical diagnosis of IA.
Methods
Preparation of fungal and bacterial cultures
All the strains were isolated from clinical patients. The
tested strains consisted of: Aspergillus (15 strains), including
A. fumigatus (four strains), A. niger (five strains), A. flavus
(four strains), A. nidulans (one strain), and A.
terreus (one strain); Candida (24 strains), including
C. albicans (12 strains), C. tropicalis (four strains),
C. parapsilosis (three strains), C. pseudotropicalis
(one strain), C. stellatoidea (one strain), C. krusei
(one strain), and C. lipolytica (one strain); Monilia
guilliermondii (one strain); and assorted bacteria (10
strains) including Staphylococcus aureus, Streptococcus
pneumoniae, Neisseria meningitidis, Shigella, Haemophilus
parainfluenzae, Escherichia coli, Klebsiella pneumoniae
(two strains), and Bacterium aeruginosum (two strains).
Czapek’s agar and Sabouraud’s agar (Beijing AoBoXing
Bio-Tech Co., Ltd., China) were inoculated with
conidiospores from Aspergillus mycelia and Candida,
respectively. Both were incubated at 30°C for 18–72 h
until a mycelial mat formed. Blood agar, chocolate agar,
and Mueller-Hinton agar plates (Beijing Laboratory
Biology Technology of China, Beijing, China) were
inoculated with different bacterial species and incubated
at 37°C for 12–16 h. A proportion of the mycelial mat
weighing approximately 10–20 mg was harvested with
sterile forceps and placed into a sterile 1.5-mL Eppendorf
tube with 600 μL of phosphate-buffered saline (PBS).
Patient group
Seventy-two patients with hematological malignancies
suffering from fever, four patients at normal temperature,
and 10 healthy volunteers who visited our Hematology
Department and Bone Transplantation Center between
September 2010 and April 2011 were enrolled in the
study. The study protocol was approved by the
author’s institutional ethics committee, namely the
Ethics Committee of General Hospital of Chinese Peoples’
Liberation Army, and was conducted in accordance with
the Declaration of Helsinki. Written informed consent
was obtained from all participants prior to specimen
collection. Five-milliliter ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood samples were collected
when the patients were febrile [19], which was defined as
an axillary temperature > 38.3°C on a single occasion or
temperature > 38°C for >1 h (according to the National
Comprehensive Cancer Network). An aliquot of 200 μL of
plasma was centrifuged from the whole blood and total
DNA was extracted from the plasma and the remnant
whole blood. We then prospectively viewed the charts,
electronic medical records, and laboratory records of these
patients for the prior 60 days. IA was diagnosed on the
basis of the revised European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy
and Infectious Diseases Mycoses Study Group (EORTC/
MSG) criteria [20]. Using these definitions, we classified the
study population into four probability levels: proven IA,
probable IA, possible IA, and no IA.
DNA extraction
(i) From fungal specimens
The mycelial mats harvested in PBS were centrifuged for
1 min at 9,000 × g, and DNA was then extracted
using a Biospin Fungus Genomic DNA Extraction Kit
in accordance with the manufacturer’s instructions
(BioFlux, China). In this process, a sample is first
lysed in LE buffer, and then DNA in the sample is liberated.
After DA buffer is added and the mixture is centrifuged at
14,000 × g for three minutes, the impurity is discarded. Re-
leased DNA is bound exclusively and specifically to
the Biospin membrane in the presence of E Bingding
Buffer under appropriate salt iron and pH conditions.
Denatured proteins and other contaminants are removed
by several washing procedures. The DNA is then
eluted from the membrane using 30 μL of elution
buffer.
(ii) From bacterial specimens
The bacterial harvest was centrifuged for one min at
12,000 × g, while genomic DNA was extracted using a
Bacterial DNAout Kit according to the manufacturer’s in-
structions (Andy Bio, USA) for gram-positive and -negative
bacteria.
(iii) From clinical specimens
Total DNA was simultaneously extracted from whole
blood and 200 μL of supernatant plasma that had been
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centrifuged from the whole blood. Red blood cell lysis
solution (Solarbio, China) was used to remove the red
blood cells from the whole blood and obtain a white
blood cell sediment. LE buffer was added to the white
blood cells or 200 μL of plasma, and the following DNA
extraction steps were undertaken in accordance with the
manufacturer’s instructions of the Biospin Kit used for the
fungal specimens. A 30-μL elution volume of DNA was
ultimately obtained [19]. Human DNA was extracted
using a DNA Purification Kit (Promega, USA) according
to the relevant protocols.
As controls, an array of known positive samples from
A. fumigatus and known negative samples from C.
albicans was included in every set of DNA extractions.
A maximum of 12 samples, including one positive and
one negative control, was processed at any given time.
The DNA concentration was determined from the ab-
sorbance at 260 nm measured using a UV spectrometer
(Amersham Biosciences Co., USA).
Primer and probe design
Ribosomal subunit gene sequences of Aspergillus were
accessed in NCBI GenBank (accession no. EF634384.1)
and aligned using BLAST. Potential primer-binding sites
were selected from the sequences conserved among
Aspergillus (EF634384.1, 353–953 bp) but not among
the human genome and other clinical relevant fungal
genera except for Penicillium and Paecilomyces species.
Primers were designed with the aid of Primer Express
3.0 software (Applied Biosystems,USA). The following
primers targeting the 28S-ITS2 region of the ribosomal
subunit gene, which was not examined in earlier studies,
were used: forward primer, 5′-GTCCGGTCCTCGAGCG
TAT-3′ (435–453); and reverse primer, 5′-GTTCAGCGG
GTATCCCTACCT-3′ (534–554). They are approximately




TAGGGATACCCGCTGAAC (EF634384.1, 435–554 bp;
ITS2, 435–521 bp; 28S, 522–554 bp). The hydrolysis
probe sequence was fluorescence labeled with 6-
carboxyfluorescein at the 5' end as the reporter dye
and None Fluorescence Quencher modified by Minor




To minimize contamination, the PCR assays were set up
in a class 2 laminar flow cabinet in a separate room from
the DNA extractions. The qPCR procedure was
performed using 40-μL reaction mixes on Mx3000P
(Stratagene, USA). Each reaction contained 20 μL of 2×
QuantiTect Probe PCR Master Mix Buffer (Qiagen,
Germany), 1 μL of each primer, 0.5 μL of the probe
(American Biosystems, USA), 6 μL of template DNA,
and 11.5 μL of RNase-Free Water (Qiagen). The
conditions for the qPCR were as follows: 50°C for
2 min to digest the PCR products including dUMP
using uracil-N-glycosylase; 95°C for 10 min to activate
a hot start DNA polymerase; and 40 cycles of
denaturing at 94°C for 15 sec and annealing and
extension at 59°C for 1 min. Each sample was processed in
a set of two counterparts. When the difference in the
quantification cycle (Cq) value of the two counterparts was
>1, the sample processing was repeated in another qPCR
set until the Cq difference was <1 cycle to ensure concord-
ance and accuracy. Two positive controls containing copies
of A. fumigatus, two negative controls containing copies of
C. albicans, and two blank controls containing water were
also included with each run to monitor inter-assay
consistency. All DNA extractions and qPCR procedures
were performed with the operator blinded to the strains’
species and the patients’ clinical features. The results were
shown by initial quantity (copies/μL).
Standard preparation
The amplified DNA products of A. fumigatus were run
on a 1.8% agarose gel and extracted using a QIAquick
Gel Extraction Kit according to the manufacturer’s
instructions (Qiagen). The purified target DNA was
ligated into a pGEM-TEasy Vector System I (A1360;
Promega), while the recombinant plasmid was
transformed into Escherichia coli-competent DH5α cells
(Beijing BioMedTech Co., Ltd., China) and extracted using
a Wizard Plus SV Miniprep DNA Purification Kit
(Promega) according to the manufacturer’s instructions.
The recombinant plasmid DNA was run on an agarose gel
with positive and negative controls and then amplified
and identified. The predicted product size was 120 bp.
The transformation was also confirmed by sequencing
the target fragment using liquid cultures of E. coli. After
identification, the recombinant plasmid DNA was diluted
10-fold from 1 × 109 copies/μL to 1 × 103 copies/μL with
RNase-free water (Qiagen) for a series of standard qPCR
F P ITS2 28S
435 453 458 474 521 534 554R
Figure 1 The target sequence, primer, and probe. The 1,154-bp
sequence of ribosomal DNA includes an 18S ribosomal RNA gene, a
partial sequence (<0–12 bp), internal transcribed spacer 1 (ITS-1,
13–195 bp), the 5.8S ribosomal RNA gene (196–352 bp), internal
transcribed spacer 2 (ITS-2, 353–521 bp), 28S ribosomal RNA gene, and
a partial sequence (522–>1,154 bp). The target sequence (435–554)
includes ITS2 and 28S as well as the partial sequence 28S-ITS2.
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preparations used to generate the standard curve. Each
sample was processed in a set of triplicate counterparts.
Calculation of Aspergillus qPCR cut-off value
Both cases of proven and probable IA were assumed to
be true. The other patients and the 10 healthy volunteers
were considered non-IA in the analysis. The initial qPCR
copies for every case were included in the calculation.
The cut-off value of the qPCR was determined using
receiver operating characteristic (ROC) analysis. Sensitivity
and specificity were calculated using IA cases as the
reference standard.
Statistical analysis
Continuous variables were compared using a non-
parametric test (Mann–Whitney U test). Two-tailed
P values < 0.05 were considered statistically significant.
An appropriate qPCR cut-off value was estimated using
ROC analysis. Statistical analyses were performed using
SPSS software version 19.0 (IBM, USA).
Results
Real-time qPCR development
The qPCR protocol was optimized with respect to primer
and probe concentrations, DNA template quantities, buffer
composition, number of cycles, and cycle parameters (data
not shown). The qPCR yielded positive results for all 15
tested isolates of Aspergillus: the mean Cq value was 21.66
(95% confidence interval [CI], 20.05–23.27), while the mean
initial number of DNA copies was 2.47 × 106/μL (95% CI,
1.69 × 105–5.11 × 106/μL). None of the 24 Candida
samples or the 10 bacterial and human DNA samples
tested was amplified. Thus, the analytical specificity of this
method was 100%. The use of serial 10-fold dilutions of A.
fumigatus DNA in water showed that the qPCR limit of de-
tection was one copy per microliter of DNA with the Cq
value around 37, while the analytical sensitivity was
six copies of DNA.
The recombinant plasmid DNA was identified by running
on an agarose gel and sequencing. It was then diluted for a
series of standard preparations and subjected to qPCR. The
standard curve was Cq = −3.332 × log (initial quantity,
copies/μL) + 40.75 (RSq = 0.991; Eff = 99.6%).
Characteristics of the study population
A total of 72 patients (30 women, 42 men) were included
in the study (Table 1). The median age was 42.5 years
(range, 3–76 years). Forty (55.6%) patients had acute
leukemia, while the other 25 (34.7%) had undergone
HSCT. According to the EORTC/MSG criteria [20], IA
was diagnosed in 41 patients (four patients with proven
IA confirmed via lung biopsy, 18 with probable IA, and 19
with possible IA), and the 28S-ITS2 qPCR results
(median, range) for proven, probable, and possible IA
were 123.47 (25.96–266.95), 43.65 (0–549.5), and 16.15
(0–98.76) copies/μL (Table 2). No amplification was seen
in the controls (four patients with normal temperature
and the 10 healthy volunteers). Febrile neutropenia
was the most common in-host factor, while the halo
sign (78%) was the most common clinical criterion.
No patients were tested using the galactomannan
(GM) test, and the mycological criteria were judged
mainly according to sputum microscopic evaluation
or culture results (Table 2).
Calculating the cut-off value for the Aspergillus 28S-ITS2
qPCR
Whole blood and plasma samples were simultaneously
collected from the patients for Aspergillus DNA isolation
Table 1 Clinical features of febrile patients with
hematological malignancies


























AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML,
chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia;
CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma; MDS,
myelodysplastic syndromes; MM, multiple myeloma; HSCT, hematopoietic
stem cell transplantation; IA, invasive aspergillosis.
Li et al. BMC Infectious Diseases 2013, 13:255 Page 4 of 9
http://www.biomedcentral.com/1471-2334/13/255
and purification, and the qPCR assays were then performed
using the hydrolysis probe method. Significantly greater
numbers of DNA copies were amplified by qPCR from
whole blood than from plasma (28.36 vs. 7.28, P < 0.001),
and DNA was not amplified from most of the plasma
samples. Therefore, the whole blood qPCR results were
used in the subsequent analysis. A significantly higher
median number of initial quantity was amplified from
patients with proven and probable IA (57.87 copies/μL;
range, 0–549.5) than patients without IA (P < 0.001).
Using proven and probable IA cases as the reference
standard, the area under the ROC curve (AUC) was
0.828 (95% CI, 0.733–0.923; P < 0.001). The optimal
infection point was located between a qPCR index of
21.34 (sensitivity, 95.5%; specificity, 68.8%; Youden
index, 0.643) and 25.24 (sensitivity, 90.9%; specificity,
73.4%; Youden index, 0.643) (Figure 2). According to the
ROC results and considering the clinical situation in
which the rate of missed diagnosis is very high compared
to the misdiagnosis rate, and if the diagnosis is missed in
patients with IA, the prognosis is very poor, so we chose
a threshold with a high sensitivity and a suboptimal
specificity. In this study, qPCR was considered positive
when there were ≥25 copies/μL (Table 3). Based on this
cut-off value, the diagnostic sensitivity and specificity for
IA by 28S-ITS2 real-time PCR were 90.9% and 73.4%,
respectively.
Discussion
The results of this study showed that the target region
of 28S-ITS2 is specific and applicable to the genetic
diagnosis of Aspergillus and that the whole blood qPCR
assay may be a very useful and reliable method for the
early diagnosis of IA in patients with hematological
malignancies.
Over the past decade, many researchers have explored
and evaluated PCR assays for the early diagnosis of IA
[10,21-24], while the European Aspergillus PCR Initiative
Table 2 Diagnostic criteria and 28S-ITS2 qPCR results for invasive aspergillosis
Diagnostic criteria IA category Total
(%)
(n=41)
Proven (%) (n=4) Probable (%) (n=18) Possible (%) (n=19)
Host factors
Neutropenia 4 (100) 6 (33.3) 3 (15.8) 13 (31.7)
T > 38°C with
Prolonged neutropenia 4 (100) 11 (61.1) 6 (31.6) 21 (51.2)
Immunosuppressant 1 (25) 9 (50) 9 (47.4) 19 (46.3)
Previous IFI 0 (0) 4 (22.2) 3 (15.8) 7 (17.1)
With AIDS 0 (0) 0 (0) 0 (0) 0 (0)
GVHD 0 (0) 3 (16.7) 2 (10.5) 5 (12.2)
Corticosteroids 3 (75) 4 (22.2) 7 (36.8) 14 (34.1)
Clinical criteria
Halo sign 3 (75) 17 (94.4) 12 (63.1) 32 (78)
Air-crescent sign 2 (50) 1 (5.6) 2 (10.5) 5 (12.2)
Cavity 1 (25) 3 (16.7) 0 (0) 4 (9.8)
Symptoms of LRI 3 (75) 8 (44.4) 13 (68.4) 24 (58.5)
Permanent fever 2 (50) 7 (38.9) 13 (68.4) 22 (53.7)
Mycological criteria
Positive sputum microscopy 0(0) 6 (33.3) 0 (0) 6 (14.6)
Positive sputum culture 1 (25) 5 (27.8) 0 (0) 6 (14.6)
G test positive 1 (25) 8 (44.4) 1 (5.3) 10 (24.4)
No bacterial positive 0 (0) 6 (33.3) 3 (15.8) 9 (22)
Histology
Biopsy specimen of the lung 4 (100) 0 (0) 0 (0) 4 (9.8)
qPCR results (copies/μL) (median, range) 123.47 43.65 16.15 28.12
(25.96–266.95) (0–549.5) (0–98.76) (0–549.5)
qPCR, real-time qualitative polymerase chain reaction; IA, invasive aspergillosis; IFI, invasive fungal infections; AIDS, acquired immune deficiency syndrome; GVHD,
graft versus host disease; LRI, lower respiratory infections.
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(EAPCRI) has performed a lot of meaningful work
around PCR standardization [13,19,25]. However, PCR
is still not included in the EORTC/MSG criteria [16].
Meanwhile, there is a major consensus in favor of
qPCR technology due to its sensitivity and speed
[13,16,24,26-28], especially after release of the Minimum
Information for Publication of Quantitative Real-Time PCR
Experiments (MIQE) guidelines, which has encouraged bet-
ter experimental practice for more reliable and unequivocal
interpretation of qPCR results [14,29]. A critical issue of
qPCR is the choice of the target DNA, which is highly
debated since it is directly associated with assay sensitivity
and specificity. To date, several genes have been used to
assess qPCR assay results in the diagnosis of IA [10,11,15],
and the ribosomal DNA gene region has been used more
and more frequently and shows the greatest potential
[16-18,25,29,30]. Ribosomal DNA comprises transcriptional
domains (5S, 5.8S, 18S, and 28S), which evolve relatively
slowly and have higher conservation rates, and non-
transcriptional domains (ITS1 and ITS2), which are more
variable [31]. A multicenter study comparing the use of the
28S and 18S primer sets targeting the D1–D2 region of the
large ribosomal subunit gene revealed that the former was
more specific, probably because when the 18S region
is targeted, a portion of the human rDNA gene needs
to be amplified, especially in the absence of A.
fumigatus DNA [18,32].
Overall, use of the 28S primer set is more suitable
than the 18S primer set for the diagnosis of Aspergillus.
The primers in our study were derived from the 28S-ITS2
region in the GenBank database and targeted both the
conservative and variable regions as described before,
while the probe was modified by minor groove binder,
which further confirmed its specificity. The target
sequence was aligned using BLAST and tested for analytic
sensitivity and specificity using 15 Aspergillus species, 24
Candida species, 10 bacterial species, and serial 10-fold
dilutions of A. fumigatus DNA, with the results of 6 copies
and 100%, respectively, indicating the applicability of the
Aspergillus qPCR assay.
With regard to the best blood fraction to test,
specimen choice had critical implications in the
extraction methodology and PCR results. Historically,
the pathogenesis of IA has been poorly understood,
and knowledge regarding the source of Aspergillus nucleic
acids in the blood is limited with no consensus having been
achieved to date. Testing serum specimens using PCR is
dependent on the detection of free circulating Aspergillus
DNA, while the use of EDTA-anticoagulated whole blood
samples allows for the detection of conidia, hyphal
fragments, and freely circulating DNA [12,18]. In our study,
plasma and whole blood were compared for Aspergillus
DNA extraction, and the results showed greater numbers
of initial DNA copies in whole blood than in plasma.
Thus, whole blood was the better specimen for
Aspergillus DNA extraction, a finding that was
consistent with those of earlier reports and the EAPCRI
recommendation [12,13,33].
To initially assess the clinical applicability of this
Aspergillus qPCR, 86 blood samples from 86 individuals












Figure 2 The receiver operating characteristic (ROC) analysis. The ROC curve and table of statistics for the cut-off value for the group of
patients with proven and probable invasive aspergillosis were used as standards.
Table 3 The diagnostic results of qPCR and EORTC/MSG
criteria
Reference standard








No IA 10 35
Total 37 49 86
qPCR, real-time qualitative polymerase chain reaction; EORTC/MSG, European
Organization for Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and Infectious
Diseases Mycoses Study Group; IA, invasive aspergillosis.
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hematological malignancies, while 41 were diagnosed with
IA according to clinical criteria. The qPCR results and
clinical data were analyzed using ROC [27]. The main
obstacle we encountered was that the number of proven
cases of aspergillosis was too low to be used as the sole
criterion for diagnosis since the blood cultures were
almost always negative for Aspergillus species. The
probability of confirming the diagnosis histopathologically
was also low because patient status was not suitable for
invasive diagnostic procedures. According to the qPCR
results, the proven and probable cases were defined as be-
ing within the reference standard category on the basis of
the EORTC/MSG criteria, the only accepted tool,
although it has some limitations [20,34].
The choice of an optimal cut-off value depends on the
test purpose. An ROC analysis was conducted that
revealed a good AUC value (0.828). In clinical practice,
there are few effective clinical approaches for the diagnosis
of IA; once a diagnosis is missed, patient prognosis is very
poor. Hence, we chose a qPCR index that yielded an
adequately high sensitivity, an acceptable false-positive
rate (1-specificity), and a better Youden index, which
reflects integrated diagnostic ability. In the ROC analysis,
a cut-off value of 25.24 seemed to yield the optimal
trade-off (Figure 2). The qPCR cut-off value of ≥25
copies/μL was tentatively established as the most suitable
for obtaining a high yield in clinical screening for IA,
while the Cq value was 36, consistent with that of the
EAPCRI report (mean, 35.3; upper limit, 38.8 cycles) [13].
According to this threshold value, the diagnostic sensitiv-
ity and specificity were 90.9% and 73.4%, respectively,
while meta-analysis showed that these values would
be 88% (95% CI, 75–94%) and 75% (95% CI, 63–84%)
if only a single positive sample was required [35]. With this
threshold, the specificity (73.4%) seemed suboptimal, and
41% (7/17) of the patients with false-positive results were
diagnosed as possible IA and 59% (10/17) were diagnosed
as no IA, which accounted for the possible IA and no IA
rates of 37% (7/19) and 22% (10/45), respectively (Table 3).
We analyzed these patients and speculated that their
degraded diagnoses were mainly due to the limitations of
the EORTC/MSG criteria [34] and the fact that high sensi-
tivity can also cause false-positive results due to low-level
contamination [36]. Due to the heterogeneity of the differ-
ent studies, there is no way to compare them. Of course,
increasing the size of the study population, especially the
number of proven cases, may result in a better cut-off
index and a more suitable guide for the presumptive
diagnosis of IA in future studies.
Another limitation of this study was that we did
not collect serial specimens for qPCR since we imme-
diately administered empirical antifungal treatment to
patients with neutropenic fever, which was thought to
affect the diagnostic detection [37]. Otherwise, no
association was found between Aspergillus DNA de-
tection and treatment efficacy or patient outcome
[38-41], the probable reason for this being the lower
DNA loads in the blood, which made reliable quanti-
fication difficult due to the random dispersion of the
few available DNA copies [39]. The current use of As-
pergillus qPCR as a diagnostic screening tool is
recommended instead of evaluation for therapy, and a
single PCR-negative result is sufficient to exclude the
diagnosis of IA because of this assay’s high sensitivity
[10,16,42]. The GM test was not performed simultaneously
with the one-time qPCR for each patient in this study since
Aspergillus GM and DNA release do not occur in a parallel
fashion due to IA pathogenesis and host factor changes that
occur over time [43-45]. Additionally, several studies have
indicated that qPCR was comparable or better to GM for
IA diagnosis and that it is more scientific and appropriate
to combine GM and qPCR for IA diagnosis [42,45-47].
Conclusions
Here we found a specific sequence of Aspergillus
28S-ITS2 for qPCR that offers good sensitivity and
specificity. This assay was initially assessed in patients
with hematological malignancies, and a tentative cut-off
value for the diagnosis of IA was obtained. Future
clinical studies are necessary, especially diagnostic
randomized controlled trials for this assay using the
novel superior DNA extraction method and ultraclean
production according to the MIQE guidelines [14,36,43].
We expect that this qPCR assay will be useful for
early diagnosing to enable the initiation of preemptive
IA treatment.
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